bioMérieux Launches Predictive Diagnostics, Pairing Microbiology Solutions with Data Science, Sequencing and Predictive Modeling
Predictive Diagnostics uses traditional core microbiology solutions alongside data science, sequencing applications and predictive modeling to help move food producers from being reactive to being proactive.
October 26, 2020—Chicago, IL—bioMérieux, a world leader in the field of in vitro diagnostics, today announced the launch of Predictive Diagnostics – a new offering for food quality and safety programs. Predictive Diagnostics uses traditional core microbiology solutions alongside data science, sequencing applications and predictive modeling to help move food producers from being reactive by detecting and responding to safety and quality issues, to being proactive by predicting and preventing them.
According to recent data from the Centers for Disease Control and Prevention, roughly 48 million people in the U.S. (1 in 6) get sick, 128,000 are hospitalized and 3,000 die each year from foodborne disease. Regulations for food producers and manufacturers are shifting as the FDA and other global governing bodies are calling for innovative technologies to evolve food safety and quality solutions by shifting the focus from responding to foodborne illness to preventing it.
“As we reflect on the historic commitment of bioMérieux and the solutions we provide, we are inspired to lead an emerging era,” said Patrice Chablain, Global R&D Director – Food at bioMérieux. “We look forward to these new times where good science, robust data and smart applications will make a powerful difference in public and consumer health.”
At the center of Predictive Diagnostics are data science and bioinformatics. Every farm, factory and manufacturing facility outputs large amounts of data, and while some is monitored and recorded, a vast amount goes unanalyzed. This data can provide key insights into the health of its facility, suppliers, environment, and the final product.
“Anyone can collect data, but at bioMérieux, we have the expertise to distill data into new insights, actions and value,” said Hannes Pouseele, Sr. Director of Strategic of Initiatives for bioMérieux. “Under Predictive Diagnostics, our data analytics team is partnering with our diverse global customer base to answer bigger questions, solve more complex problems and ultimately enable our customers to make safe, quality food with increased control and overall performance.”
bioMérieux’s suite of core lab and at-line microbiology tools will support the Predictive Diagnostics mission. For more information about the new offering, visit Predictive-Diagnostics.com.
A world leader in the field of in vitro diagnostics for over 55 years, bioMérieux is present in 44 countries and serves more than 160 countries with the support of a large network of distributors. In 2019, revenues reached €2.7 billion, with over 90% of sales outside of France.
bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
bioMérieux is listed on the Euronext Paris stock market
Symbol: BIM – ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP
Joy Dell'aringa 224.213.1756
bioMérieux Corporate Industry Head Office
Olivia Seward +33 (0) 668740207
Austin Isbell 801.631.3256